# IICS4all: Multi-national Investigator-Initiated Clinical Studies in Cardiovascular, Autoimmune, Metabolic, and Non-Communicable Respiratory Diseases, including Underrepresented Populations

**Funder:** Research Council of Norway
**Budget:** €1.3M
**Deadline:** 14 January 2027 (Full proposal deadline 14 June 2027)
**Consortium:** Required — transnational multi-national clinical study consortium
**Application:** 2-stage: pre-proposal (14 January 2027) → full proposal (14 June 2027)
**TRL:** 3-6
**Eligible countries:** NO
**Official call:** https://www.forskningsradet.no/en/call-for-proposals/International-joint-calls/multi-national-investigator-initiated-clinical-studies-cardiovascular-autoimmune-metabolic-non-communicable-respiratory-diseases-underrepresented-populations/
**Last updated:** 15 Nov 2026

## Eligibility & scope

Joint announcement with Regional Health Authorities for transnational investigator-initiated clinical trials; supports pragmatic phase III randomised controlled multi-national clinical studies, including underrepresented populations.

## Summary

IICS4all, funded through the Research Council of Norway under the ERA4Health partnership, supports investigator-initiated phase III randomised controlled clinical studies in cardiovascular, autoimmune, metabolic and non-communicable respiratory diseases, including studies covering underrepresented populations. The Norwegian allocation is €1.3M, provided jointly with the Regional Health Authorities, and applies to multi-national consortia submitting pragmatic, interventional trial proposals. The call runs as a two-stage process, with a pre-proposal ahead of the full proposal submission.

## Who should apply

- Investigators leading pragmatic phase III randomised controlled trials
- Researchers based at Norwegian institutions participating in a multi-national consortium
- Studies in cardiovascular, autoimmune, metabolic or non-communicable respiratory disease
- Projects designed to include underrepresented populations
- Clinical teams with trial-ready interventions at TRL 6-7

## Key dates

- Pre-proposal deadline 14 January 2027, full proposal deadline 14 June 2027
- Two-stage process: pre-proposal then full proposal
- Norwegian funding stream delivered jointly with the Regional Health Authorities

## Tips for applicants

- Confirm the multi-national consortium structure required under ERA4Health before the pre-proposal stage, since this is a joint call across partner countries.
- Frame the study as pragmatic and phase III with clear interventional design, the call specifically excludes earlier-phase or purely observational work.
- Address the underrepresented populations scope explicitly in the proposal, as it is named as a distinct focus of the call.

## Frequently asked questions

### How much funding is available for IICS4all in Norway?

The Norwegian allocation is €1.3M, provided jointly by the Research Council of Norway and the Regional Health Authorities.

### What is the deadline for IICS4all?

The pre-proposal deadline is 14 January 2027, followed by a full proposal deadline of 14 June 2027.

### Is a consortium required for IICS4all?

Yes, a multi-national consortium is required as part of the ERA4Health partnership.

### What diseases does IICS4all cover?

The call funds studies in cardiovascular, autoimmune, metabolic and non-communicable respiratory diseases, including those involving underrepresented populations.

### What type of clinical studies does IICS4all fund?

It funds pragmatic, phase III, randomised controlled, multi-national interventional investigator-initiated clinical studies.

---

Source: [The Great Grantsby](https://grantsby.eu/grants/research-council-of-norway-iics4all-multi-national-investigator-initiated-cli-2027-01) — EU grant monitoring for academic researchers. Always verify details on the funder's website before applying.

**See which EU calls match your profile.** [Preview your matches in 30 seconds, no signup](https://grantsby.eu/demo?ref=llm_grant_md&grant=research-council-of-norway-iics4all-multi-national-investigator-initiated-cli-2027-01).